Literature DB >> 19835824

Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs.

Bappaditya Dey1, Ruchi Jain, Aparna Khera, Vivek Rao, Neeraj Dhar, Umesh D Gupta, V M Katoch, V D Ramanathan, Anil K Tyagi.   

Abstract

Owing to its highly immunodominant nature and ability to induce long-lived memory immunity, ESAT-6, a prominent antigen of Mycobacterium tuberculosis, has been employed in several approaches to develop tuberculosis vaccines. Here, for the first time, we combined ESAT-6 based recombinant BCG (rBCG) and DNA vaccine (DNAE6) in a prime boost approach. Interestingly, in spite of inducing an enhanced antigen specific IFN-gamma response in mice, a DNAE6 booster completely obliterated the protection imparted by rBCG against tuberculosis in guinea pigs. Analysis of immunopathology and cytokine responses suggests involvement of an exaggerated immunity behind the lack of protection imparted by this regimen.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19835824     DOI： 10.1016/j.vaccine.2009.09.121

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

Authors:  Michael J Brennan; Bartholt Clagett; Hillary Fitzgerald; Vicki Chen; Ann Williams; Angelo A Izzo; Lewellys F Barker
Journal:  Vaccine       Date:  2012-03-03       Impact factor: 3.641

2.  A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice.

Authors:  Haniyeh Aghababa; Ashraf Mohabati Mobarez; Nima Khoramabadi; Mehrdad Behmanesh; Mehdi Mahdavi; Majid Tebianian; Mehdi Nejati
Journal:  Mol Biotechnol       Date:  2014-06       Impact factor: 2.695

Review 3.  Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Authors:  Joseph M Cicchese; Stephanie Evans; Caitlin Hult; Louis R Joslyn; Timothy Wessler; Jess A Millar; Simeone Marino; Nicholas A Cilfone; Joshua T Mattila; Jennifer J Linderman; Denise E Kirschner
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

4.  Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.

Authors:  Fu-Ying Dai; Jun-Fang Wang; Xue-Li Gong; Lang Bao
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

Review 5.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

6.  Guinea pig models for translation of the developmental origins of health and disease hypothesis into the clinic.

Authors:  Janna L Morrison; Kimberley J Botting; Jack R T Darby; Anna L David; Rebecca M Dyson; Kathryn L Gatford; Clint Gray; Emilio A Herrera; Jonathan J Hirst; Bona Kim; Karen L Kind; Bernardo J Krause; Stephen G Matthews; Hannah K Palliser; Timothy R H Regnault; Bryan S Richardson; Aya Sasaki; Loren P Thompson; Mary J Berry
Journal:  J Physiol       Date:  2018-05-30       Impact factor: 5.182

7.  Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.

Authors:  Jia Lu; Chun Wang; Zhiguang Zhou; Ying Zhang; Tingting Cao; Chunwei Shi; Zhenhua Chen; Lingxia Chen; Changxue Cai; Xionglin Fan
Journal:  Clin Dev Immunol       Date:  2011-02-27

8.  Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model.

Authors:  Anouk C M Platteel; Natalie E Nieuwenhuizen; Teresa Domaszewska; Stefanie Schürer; Ulrike Zedler; Volker Brinkmann; Alice J A M Sijts; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

9.  Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B.

Authors:  Chun Wang; Ruiling Fu; Zhenhua Chen; Kun Tan; Lingxia Chen; Xindong Teng; Jia Lu; Chunwei Shi; Xionglin Fan
Journal:  Clin Dev Immunol       Date:  2012-04-18

Review 10.  Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory.

Authors:  Adeliane Castro da Costa; Sarah Veloso Nogueira; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Front Immunol       Date:  2014-04-07       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.